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Bivalirudin versus heparin during percutaneous coronary intervention:
a meta-analysis of randomized trials
Salvatore Cassese1, Robert Byrne1, Heribert Schunkert1, Peter B. Berger2,
Adnan Kastrati1
1Deutsches Herzzentrum, Munich, Germany, 2Geisinger Health System, Danville, PA
Background: Current recommendation on the use of bivalirudin in patients under-
going percutaneous coronary intervention (PCI) are mostly based on trials comparing
bivalirudin versus heparin plus planned glycoprotein IIb/IIIa inhibitor (GPI). Whether
bivalirudin is also superior to heparin alone is still not fully established. This meta-
analysis investigates the efﬁcacy and safety of bivalirudin versus heparin in patients
treated with PCI and provisional or bailout GPI use.
Methods: Scientiﬁc databases and websites were searched. The primary efﬁcacy and
safety outcomes were the 30-day incidence of death and major bleeding, respec-
tively. The secondary outcomes were the 30-day incidence of myocardial infarction
(MI), deﬁnite stent thrombosis (ST) and urgent target vessel revascularization
(TVR). Odds ratio (OR) and 95% conﬁdence interval [95% CI] served as summary
statistics.
Results: A total of 18,065 PCI-patients randomized to bivalirudin (n¼ 9,033)
versus heparin (n¼ 9,032) were studied. At 30 days, bivalirudin versus heparin
shows comparable risk of death (1.09 [0.83-1.41], p¼ 0.54), lower risk of major
bleeding (0.57 [0.40-0.80], p¼ 0.001), higher risk of deﬁnite ST (2.09 [1.26-3.47],
p¼ 0.005), comparable risk of MI (1.10 [0.83-1.46], p¼ 0.50) with a trend to-
wards a higher risk of urgent TVR (1.37 [0.96–1.96], p¼ 0.08). In particular, the
risk of acute ST (within 24 hours) is increased by bivalirudin (3.48 [1.66-7.28],
p< 0.001).
Conclusions: In patients treated with PCI, bivalirudin versus heparin does not reduce
mortality. The lower risk of major bleeding is achieved at the expense of a higher risk
of acute ST.
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Bivalirudin Versus Unfractionated Heparin in Percutaneous Coronary
Intervention for Stable Angina: A Randomized Clinical Trial (STATUS-PCI)
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Background: Few direct comparisons between unfractionated heparin (UFH) mon-
otherapy vs. bivalirudin (Angiomax, The Medicine’s Company Inc., Parsippany, NJ)
for percutaneous coronary intervention (PCI) in patients with stable angina exists in
the modern era of dual anti-platelet therapy.
Methods: STATUS-PCI is a prospective, investigator initiated, single-center, single-
blinded, randomized 1:1 trial of UFH vs. bivalirudin in patients with stable angina
or silent ischemia on non-invasive stress testing undergoing PCI of 1 or more
>70% coronary stenosis. The primary endpoint of the study was comprised of
major and minor bleeding events (deﬁned by the REPLACE-2 trial deﬁnition)
during the index hospitalization and up to 30 days. Secondary endpoints included
major adverse cardiac events (MACE) comprising all-cause mortality, myocardial
infarction (MI), ischemia driven target vessel revascularization (TVR), and cerebral
vascular accident (CVA) and net adverse cardiac events (NACE), deﬁned as a
composite of MACE and any bleeding event at 30 days. Based on chi-square
testing with the signiﬁcance level of 0.05 and a power of 0.80, 388 patients in each
group (with continuity correction) are required to show a 50% relative decrease in
bleeding in the bivalirudin arm, assuming a 12% rate of bleeding in the control arm
(i.e. UFH).
Results: The study was halted prematurely for futility by the data safety monitoring
board after enrollment of 260 patients. There were no signiﬁcant differences in
baseline characteristics between the 2 groups. Radial access was used in 28.5% vs.
23.4% (p¼0.348) and closure devices were used in 50.8% vs. 55.6% (p¼0.447) in the
UFH and bivalirudin groups, respectively. The primary endpoint occurred in 22 pa-
tients (8.5%) without a signiﬁcant difference between the groups (11 [8.9%] vs. 11
[8.0%], p¼0.808). MACE at 30 days occurred in 0 vs. 3 (2.2%) [p¼0.10] and NACE
in 11 (8.9%) vs. 14 (10.2%) [p¼0.71] patients in the UFH and bivalirudin groups,
respectively.
Conclusions: Among patients with stable ischemic heart disease undergoing PCI on
dual anti-platelet therapy, there was no signiﬁcant difference between UFH and
bivalirudin with respect to bleeding events or MACE at 30 days.JACC Vol 64/11/Suppl B j September 13–17, 2014 j TCT Abstracts/PhTCT-462
Heparin versus Bivalirudin in patients undergoing Percutaneous Coronary
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1Fremantle Hospital, Fremantle, WA
Background: Anti-platelet and anti-coagulant adjunctive therapies are associated
with an increased risk of major bleeding that adversely impacts on clinical
outcomes. Objective: To retrospectively assess the in hospital MACE and major
bleeding in patients with acute coronary syndrome (ACS) undergoing percutaneous
coronary intervention(PCI) received either unfractionated heparin (UFH) or
Bivalirudin.
Methods: Consecutive patients undergoing PCI for ACS at Fremantle Hospital
from August 2008 to December 2013 were identiﬁed. All patients were pre-treated
with dual antiplatelet therapy. Patients received intravenous UFH (50-100IU/kg)
to achieve activated coagulation time 250 to 300s or Bivalirudin (bolus 0.75 mg/kg
and Infusion 1.75 mg/kg/hr). Adjunctive glycoprotein IIbIIIa was given at the
discretion of the operator. In-hospital MACE and bleeding events were identiﬁed
from systematic review of case notes after hospital discharge and from PCI
database.
Results: 3371 patients were identiﬁed, 1741 received UFH and 1631 received
Bivalirudin. Mean age was 62.3 years in both groups (p¼0.575). Female gender was
24% vs. 26% (p¼0.10) , current smoking 66% vs. 70% (p¼0.53, and diabetes 25%
vs. 26% (p¼0.62) in UFH vs. Bivalirudin groups. 85% of patients received Clo-
pidogrel, 8% Ticagrelor and 4% Prasugrel in both groups(p¼ ns). In UFH vs.
Bivalirudin groups STEMI presentation was 28% vs. 19%, NSTEMI/USA 51% vs.
58% and elective 19% vs. 23% respectively. Trans-femoral access was used in 93%
vs. 92% (p¼0.41). More patients received GPIIbIIIa antagonists in the UFH group
(30.2% vs. 3.4%; p< 0.001). Pre-discharge stent thrombosis were noted in 1.0%
with UFH vs. 0.5% with Bivalirudin(p¼0.20). The incidence of in hospital MACE
was similar and the incidence of BARC 1(Bleeding Academic Research consortium)
was1.8% in UFH group vs. 1.1% bivalirudin group. BARC2 bleeding was 1.5%
Bivalirudin vs. UFH 2.1%(p¼0.228). BARC 5 major bleeding was 0.0% in both
groups.
Conclusions: In this PCI cohort, UFH compared with Bivalirudin was not associated
with a high incidence of in hospital MACE and major bleeding despite a signiﬁcantly
higher rate of GPIIbIIIa antagonist treatment in the UFH group.
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Background: The rate of acute (24 hours) stent thrombosis (ST) is increased with
bivalirudin anticoagulation (AC) during primary percutaneous coronary intervention
(PCI) for ST-segment elevation myocardial infarction (STEMI) compared to heparin
plus the routine use of a glycoprotein IIb/IIIa inhibitor. Prior studies suggest that pre-
PCI unfractionated heparin (UFH) may protect against acute ST, presumably due to its
longer half-life. In this regard, whether the routine use of post-PCI AC is able to
prevent ST in this setting is unknown. We therefore evaluated outcomes after routine
AC prophylaxis following primary PCI in bivalirudin-treated pts from the HORI-
ZONS-AMI trial.
Methods: 1,445 pts who received bivalirudin during primary PCI were grouped ac-
cording to use of pre-PCI UFH, post-PCI AC for routine prophylaxis, both, or neither.
Acute and 30-day rates of deﬁnite or probable ST were assessed using propensity-
adjusted multivariable analysis.
Results: 948 pts (65.6%) received pre-PCI UFH, 436 (30.2%) received post-PCI AC
for routine prophylaxis (for median 4.0 days), and 386 (26.7%) received neither. 623
pts (43.1%) received only pre-procedural UFH and 111 (7.7%) received only post-PCI
AC for routine prophylaxis. ST occurred in 13 pts (0.9%) within the ﬁrst 24 hours post
PCI and in 27 pts (1.9%) within 30 days. By multivariate analysis, post-PCI AC for
routine prophylaxis was not associated with reduced acute or 30-day ST, regardless of
whether or not pts also received pre-PCI UFH (Table).
Conclusions: In this large-scale study, post-PCI AC for routine prophylaxis following
bivalirudin monotherapy during primary PCI was not associated with a reduction in
acute or 30-day ST.armacotherapy - Procedural Anticoagulants B135
